Cartesian Therapeutics (RNAC) EPS (Weighted Average and Diluted) (2019 - 2026)
Cartesian Therapeutics (RNAC) reported EPS (Weighted Average and Diluted) of -$1.46 for Q1 2026, down 114.71% year-over-year from $9.93 in Q1 2025, and up 59.1% quarter-over-quarter from -$3.57 in Q4 2025.
Cartesian Therapeutics (RNAC) EPS (Weighted Average and Diluted) (2019 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 8 years of EPS (Weighted Average and Diluted) data on file, last reported at -$1.46 in Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$1.46, down 114.71% year-over-year; the trailing twelve-month figure through Mar 2026 was -$5.91 (down 413.91% YoY), and the FY2025 annual result was -$5.02, down 11.8% from the prior year.
- EPS (Weighted Average and Diluted) rose to -$1.46 in Q1 2026 per RNAC's latest filing, from -$3.57 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.54 in Q2 2024 and troughed at -$41.56 in Q4 2023.
- A 5-year average of -$3.96 and a median of -$1.13 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- The sharpest annual moves came in 2022 and 2023: EPS (Weighted Average and Diluted) surged 2824.07% in 2022, then tumbled 83020.0% in 2023.
- A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.05 in 2022, then plunged by 83020.0% to -$41.56 in 2023, then jumped by 100.29% to $0.12 in 2024, then slumped by 3075.0% to -$3.57 in 2025, then jumped by 59.1% to -$1.46 in 2026.
- Business Quant data shows RNAC's EPS (Weighted Average and Diluted) at -$1.46 in Q1 2026, -$3.57 in Q4 2025, and -$1.38 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Cartesian Therapeutics | 261.84 Mn | 261.84 Mn | - | -1.46 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.46 |
| Dec 31, 2025 | -3.57 |
| Sep 30, 2025 | -1.38 |
| Jun 30, 2025 | 0.50 |
| Mar 31, 2025 | -0.68 |
| Dec 31, 2024 | 0.12 |
| Sep 30, 2024 | -1.13 |
| Jun 30, 2024 | 0.54 |
| Mar 31, 2024 | -10.50 |
| Dec 31, 2023 | -41.56 |
| Sep 30, 2023 | -1.74 |
| Jun 30, 2023 | -2.23 |
| Mar 31, 2023 | -4.24 |
| Dec 31, 2022 | -0.05 |
| Sep 30, 2022 | -0.05 |
| Jun 30, 2022 | 0.06 |
| Mar 31, 2022 | 0.08 |
| Dec 31, 2021 | 0.12 |
| Sep 30, 2021 | -0.16 |
| Jun 30, 2021 | 0.00 |